MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975.

Minhong TangShane O'GradyJohn CrownMichael J Duffy

Published in: Breast cancer research and treatment (2022)

Our findings open the possibility of targeting MYC for the treatment of TNBC. Based on our results, we suggest that trials use a combination of MYCi975 and either docetaxel or doxorubicin and include MYC as a putative therapy predictive biomarker.

Keyphrases

transcription factor
cancer therapy
stem cells
minimally invasive
radiation therapy
mesenchymal stem cells